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Abstract
Postprandial secretion of glucagon-like peptide-1 (GLP-1) is enhanced after
Roux-en-Y gastric bypass (RYGB), but the precise molecular mechanisms
explaining this remain poorly understood. Plasma concentrations of bile acids
(BAs) increase after RYGB, and BAs may act as molecular enhancers of GLP-1
secretion through activation of TGR5-receptors. We aimed to evaluate GLP-1
secretion after oral administration of the primary bile acid chenodeoxycholic
acid (CDCA) and the secondary bile acid ursodeoxycholic acid (UDCA)
(which are available for oral use) in RYGB-operated participants. Eleven par-
ticipants (BMI 29.1  1.2, age 37.0  3.2 years, time from RYGB
32.3  1.1 months, weight loss after RYGB 37.0  3.1 kg) were studied in a
placebo-controlled, crossover-study. On three different days, participants
ingested (1) placebo (water), (2) UDCA 750 mg, (3) CDCA 1250 mg (highest
recommended doses). Oral intake of CDCA increased plasma concentrations
of GLP-1, C-peptide, glucagon, peptide YY, neurotensin, total bile acids, and
fibroblast growth factor 19 significantly compared with placebo (all P < 0.05
for peak and positive incremental area-under-the-curve (piAUC)). All plasma
hormone concentrations were unaffected by UDCA. Neither UDCA nor
CDCA changed glucose, cholecystokinin or glucose-dependent insulinotropic
polypeptide (GIP) concentrations. In conclusion, our findings demonstrate
that the primary bile acid chenodeoxycholic acid is able to enhance secretion
of gut hormones when administered orally in RYGB-operated patients—even
in the absence of nutrients.
Introduction
Roux-en-Y gastric bypass (RYGB) is an effective treat-
ment of severe obesity (Sj€ostr€om 2013; Madsbad et al.
2014) and type 2 diabetes (Madsbad et al. 2014; Schauer
et al. 2014). Interestingly, improved glycemia occurs
within days after surgery indicating that weight-loss can-
not fully explain improvement in glucose tolerance (Por-
ies et al. 1995). Early improvement in hepatic insulin
sensitivity (Bojsen-Moller et al. 2014), accelerated absorp-
tion of nutrients (Dirksen et al. 2013a), altered gut hor-
mone secretion (Jacobsen et al. 2012), and enhanced
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insulin secretion (Jacobsen et al. 2012) all appear to con-
tribute to the weight loss and improved glucose metabo-
lism seen postoperatively. After RYGB, studies have
consistently reported a 7–10 fold enhanced postprandial
secretion of glucagon-like peptide-1 (GLP-1), which is of
major importance for the improved beta-cell function in
patients with preoperative type 2 diabetes (Jørgensen
et al. 2012, 2013) and linked to postoperative weight loss
(Dirksen et al. 2012). However, the mechanisms behind
the enhanced GLP-1 secretion after RYGB remain poorly
understood.
Several studies have demonstrated increased plasma bile
acids (BAs) after RYGB (Nakatani et al. 2009; Jansen
et al. 2011; Pournaras et al. 2012; Ahmad et al. 2013;
Kohli et al. 2013a; Steinert et al. 2013; Werling et al.
2013; Dutia et al. 2015; Jørgensen et al. 2015), and
endogenous BAs have therefore been proposed as key-
mediators of the improvements in glucose metabolism
(Pournaras et al. 2012; Kohli and Seeley 2013; Kohli et al.
2013b; Ryan et al. 2014; Baud et al. 2016). Moreover,
studies have demonstrated an association between plasma
BAs, GLP-1 and improved glucose tolerance months to
years after RYGB (Nakatani et al. 2009; Pournaras et al.
2012; Kohli et al. 2013a; Steinert et al. 2013; Werling
et al. 2013; Dutia et al. 2015; Jørgensen et al. 2015).
Within the first week after RYGB, GLP-1 secretion is
enhanced and glucose tolerance markedly improved while
plasma BAs still seem unchanged (Steinert et al. 2013;
Jørgensen et al. 2015), although one study reports
increased BAs already 4 days after RYGB (Pournaras et al.
2012). Hence, it remains unclear to what extent endoge-
nous BAs are involved in the exaggerated GLP-1 and
insulin responses after RYGB.
Administration of BAs has been demonstrated to
stimulate GLP-1 secretion in vitro via activation of the
TGR5 receptor, which is activated by most BAs (Kawa-
mata et al. 2003; Brighton et al. 2015). A stimulated
secretion was also observed in humans after rectal
(Adrian et al. 2012; Wu et al. 2013a) and intracolonic
infusions (Adrian et al. 1993) in non-operated healthy
volunteers (Adrian et al. 1993; Wu et al. 2013a) and
patients with type 2 diabetes (Adrian et al. 2012). In
contrast, neither intragastric nor upper intestinal
administration of BAs were associated with clinically
relevant GLP-1 responses (Meyer-Gerspach et al. 2013;
Wu et al. 2013b; Hansen et al. 2016), which might sug-
gest that an exposure of the distal small intestine is
required for BAs to stimulate robust GLP-1 secretion.
As a consequence of the bypass of stomach and upper
small intestine after RYGB, nutrients and other ingested
molecules will rapidly reach the distal part of the small
intestine where the density of GLP-1 producing L-cells
is high (Eissele et al. 1992).
The aim of our study was to evaluate whether oral
administration of BAs is able to increase GLP-1 secretion
in RYGB-operated participants. We studied intake of two
different BAs that are available as pharmacological agents
used for treatment of gallstones: the primary BA cheno-
deoxycholic acid (CDCA) and the secondary BA
ursodeoxycholic acid (UDCA). We chose to use the high-
est recommended daily dose for each bile acid according
to the label, which was 1250 mg for CDCA and 750 mg
for UDCA. We hypothesized that oral intake would sti-
mulate GLP-1 secretion in RYGB-operated participants.
Methods
Participants
Eleven (six males and five females) participants were
recruited from Hvidovre Hospital’s bariatric surgery out-
patient clinic (Table 1). Inclusion criteria were uncompli-
cated primary RYGB >3 months prior to inclusion and
normal glucose tolerance (fasting plasma glucose
<7.0 mmol/L and HbA1c <48 mmol/mol), and exclusion
criteria were anemia (plasma hemoglobin <6.5 mmol/L),
dysregulated hypothyroidism, use of anti-thyroid medica-
tion, renal insufficiency, prior pancreatitis, certain RYGB
complications (severe reactive hypoglycemia, dysphagia),
pregnancy or lactation. All participants maintained stable
weight during the study period. Medications include vita-
mins (multivitamins, zink, D-vitamins and B12-injec-
tions), proton-pump inhibitors and antihypertensive
drugs. None of the participants had cholecystectomy prior
to inclusion; however, one participant underwent acute
cholecystectomy before the last study day due to an acute
attack of simple gallstones. One participant only com-
pleted the UDCA day and another participant did not
complete the CDCA day; moreover, one participant was
excluded from data analysis from the CDCA day due to
excessively high morning C-peptide concentrations indi-
cating a non-fasting state.
Table 1. Study participants. Data are presented as mean  SEM.
n = 11
Age (years) 37.0  3.2
Time since RYGB (months) 32.3  1.1
Weight loss (kg) 37.0  3.1
Weight (kg) 90.5  5.5
Body mass index (kg/m2) 29.1  1.2
Fasting plasma glucose (mmol/liter) 4.9  0.1
HbA1c (mmol/mol) 33.2  0.9
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Written informed consent was obtained from all parti-
cipants before entering the study. The protocol was
approved by the Municipal Ethical Committee of Copen-
hagen in accordance with the Helsinki II declaration, by
the Danish Data Protection Agency and was registered at
www.ClinicalTrials.gov (NCT 02340247).
Study design
Participants were examined on three separate days sepa-
rated by at least 2 days with the following interventions:
Placebo: Oral intake of 150 mL water; UDCA: Oral
intake of UDCA 750 mg (Ursofalk capsules, Dr. Falk
Pharma GmbH, Freiburg, Germany) suspended in 50 mL
water followed by oral intake of 100 mL water; CDCA:
Oral intake of CDCA 1250 mg (Xenbilox capsules, Juers
Pharma ImportExport GmbH, Hamburg, Germany) sus-
pended in 50 mL water followed by oral intake of
100 mL water. Dosages corresponded to the highest re-
commended daily dose of CDCA and UDCA respectively.
Before the experiments, participants were instructed to
fast overnight (10–12 h). On each study day, participants
were weighed, a catheter was inserted into a forearm vein
and three basal blood samples were drawn (–10, –5 and
0 min). At t = 0 placebo, UDCA or CDCA was ingested
within 5 min. Blood was sampled frequently for a total of
3 h (at t = 5, 10, 15, 20, 25, 30, 45, 60, 90, 120,
180 min). In addition to measurements of blood pressure
and heart rate, appetite perception, nausea, and stomach
pain were evaluated using visual analogue scale (VAS)
scoring at t = 0, 30, 60, 120, 180 min.
Sample collection and laboratory analyses
Blood was collected into clot activator tubes for C-peptide
analysis and into EDTA-coated tubes for analyses of glu-
cose, GLP-1, glucagon, PYY, GIP, CCK, neurotensin, total
bile acids (TBA) and fibroblast growth factor 19 (FGF19).
Clot activator tubes were left at room temperature to
coagulate for 30 min, whereas EDTA-tubes were imme-
diately placed on ice until centrifuged at 4°C (2000g for
10 min). Plasma glucose was measured using the glucose
oxidase technique (YSI model 2300 STAT Plus; YSI, Yel-
low Springs, OH). Serum for measurements of C-peptide
was frozen and stored at 80°C and plasma at 20°C
until batch analysis.
Serum C-peptide concentrations were determined using
Immulite 2000 analyzer (Siemens Healthcare Diagnostics
Inc., Tarrytown, NY, USA). Plasma samples were assayed
for total GLP-1 immunoreactivity using antiserum 89390
as previously described (Ørskov et al. 1994). Glucagon
was measured by in-house radioimmunoassay (RIA) using
antibody 4305 (Jørgensen et al. 2012). Total PYY was
measured by an in-house RIA using a monoclonal anti-
body MAB8500 as described elsewhere (Tor€ang et al.
2016).
Total GIP was measured by in-house RIA using antibody
80867 directed against the C-terminal region (Jørgensen
et al. 2012). CCK was measured by RIA using antiserum
no. 92128, which binds all the bioactive forms of CCK in
circulation (CCK-58, -33, -22 and -8) with equal potency,
and without cross-reactivity with homologous gastrin pep-
tides (Rehfeld 1998). Neurotensin was measured by in-
house RIA employing N-terminal directed antiserum (no.
3D97), thus measuring total neurotensin (Kuhre et al.
2015). TBA concentrations were determined using an
enzyme cycling based TBA Assay Kit from Diazyme (Cat
No DZ042A-K, San Diego, CA, USA; intra-assay coefficient
of variation (CV): 3.9%, inter-assay CV: 2.9%). FGF19
concentrations were determined using a commercial
human FGF19 sandwich ELISA kit from BioVendor (Cat
No RD191107200R, BioVendor, Brno, Czech Republic;
intra-assay CV: 6.0%; inter-assay CV: 7.5%).
Statistical analyses and calculations
Basal concentrations were calculated as the mean of the
three time points (t = 10, 5 and 0 min). Positive
incremental area-under-the-curve (piAUC) was calculated
using the trapezoid rule as the AUC above basal concen-
trations to assess postprandial secretions. Data are
expressed as mean  SEM.
Differences between the three study days were analyzed
by ANOVA in a linear mixed effects model with study
day (placebo, UDCA, CDCA) as fixed effect and indivi-
dual participants as random effect. Post hoc testing was
performed comparing CDCA and UDCA with placebo if
ANOVA revealed significant differences between study
days. Statistical analysis was performed in R version 3.1.2
(www.R-projec.org) with the package “nlme” for the li-
near mixed effects models. P < 0.05 were considered sta-
tistically significant.
Results
Basal hormone concentrations
Basal hormone concentrations did not differ between
study days (Table 2).
Primary outcome: GLP-1 secretion
GLP-1 secretion differed significantly between study days
(ANOVA: piAUC P < 0.01 and peak P = 0.01). Oral
intake of CDCA increased GLP-1 secretion from a basal of
14.3  1.5 pmol/L to a mean peak concentration of
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Table 2. GLP-1, PYY, neurotensin, glucose, C-peptide, CCK, and GIP concentrations in response to bile acid administration.
Placebo
n = 10
CDCA
n = 8
UDCA
n = 11 ANOVA
Placebo
versus CDCA
Placebo
versus UDCA
Basal GLP-1
(pmol/L)
12.7  0.9 14.3  1.5 12.2  1.3 P = 0.25
Peak GLP-1
(pmol/L)
18.0  2.2 29.1  2.2 21.8  3.2 P = 0.01 P < 0.01 P = 0.18
piAUC GLP-1
(pmol/L 9 min)
226  105 815  104 444  102 P < 0.01 P < 0.01 P = 0.14
Basal PYY
(pmol/L)
11.4  0.8 8.9  2.2 10.2  1.0 P = 0.44
Peak PYY
(pmol/L)
12.9  0.8 18.5  1.6 14.0  1.0 P = 0.01 P < 0.01 P = 0.48
piAUC PYY
(pmol/L 9 min)
28.8  12.0 937  224 263  79.9 P < 0.01 P < 0.01 P = 0.17
Basal neurotensin
(pmol/L)
16.2  3.1 15.7  3.6 15.5  1.9 P = 0.77
Peak neurotensin
(pmol/L)
21.9  4.7 66.9  10.0 30.0  4.6 P < 0.01 P < 0.01 P = 0.16
piAUC neurotensin
(pmol/L 9 min)
123  45.2 2399  418 683  371 P < 0.01 P < 0.01 P = 0.16
Basal glucose
(mmol/L)
5.0  0.1 4.9  0.1 5.0  0.13 P = 0.58
Peak glucose
(mmol/L)
5.1  0.1 5.2  0.1 5.1  0.15 P = 0.98
piAUC glucose
(mmol/L 9 min)
9.7  3.6 14.6  4.6 11.5  7.9 P = 0.87
Basal C-peptide
(pmol/L)
548  52.7 483  43.1 485  41.1 P = 0.33
Peak C-peptide
(pmol/L)
592  54.2 624  59.2 557  44.9 P = 0.54
piAUC C-peptide
(pmol/L 9 min)
1716  604 7094  2506 3119  1234 P = 0.03 P = 0.01 P = 0.41
Basal glucagon
(pmol/L)
7.4  0.8 8.0  1.4 7.5  1.1 P = 0.93
Peak glucagon
(pmol/L)
9.1  1.2 13.8  2.4 9.9  1.6 P < 0.01 P < 0.01 P = 0.41
piAUC glucagon
(pmol/L 9 min)
32.8  11.6 283  58.3 60.3  23.1 P < 0.01 P < 0.01 P = 0.52
Basal CCK
(pmol/L)
0.5  0.1 0.5  0.1 0.5  0.1 P = 0.30
Peak CCK
(pmol/L)
1.3  0.2 1.8  0.4 1.1  0.2 P = 0.05 P = 0.06 P = 0.49
piAUC CCK
(pmol/L 9 min)
16.5  4.9 24.1  6.3 21.8  6.1 P = 0.57
Basal GIP
(pmol/L)
10.8  0.7 10.8  0.8 9.9  1.1 P = 0.61
Peak GIP
(pmol/L)
13.6  1.0 14.4  0.5 12.8  0.6 P = 0.37
piAUC GIP
(pmol/L 9 min)
113  39.3 162  82.4 169  80.9 P = 0.74
CDCA, chenodeoxycholic acid; UDCA, ursodeoxycholic acid. Data are presented as mean  SEM.
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29.1  2.2 pmol/L (P < 0.01 vs. placebo), whereas GLP-1
concentrations were unaffected by UDCA (Table 2,
Fig. 1A). One participant underwent cholecystectomy
before the CDCA day, but GLP-1 responses (piAUC:
1032 pmol/L 9 min, peak: 38 pmol/L) on this day did not
differ markedly from the overall mean response to CDCA.
Plasma glucose, serum C-peptide, and
plasma glucagon
Plasma glucose concentrations did not differ between
study days (Table 2, Fig. 1B). C-peptide secretion differed
between study days (ANOVA: piAUC P = 0.03) and was
slightly increased after oral intake of CDCA (P = 0.01) in
contrast to an absent response after UDCA compared
with placebo. However, peak C-peptide concentrations
were not significantly affected (ANOVA: peak P = 0.54;
Table 2, Fig. 1D). Glucagon secretion also differed
between study days (ANOVA: P < 0.01 for both piAUC
and peak) with increased secretion following CDCA but
no effect of UDCA (Table 2, Fig. 1F).
Other gut hormones
PYY secretion differed between study days (ANOVA:
P ≤ 0.01 for both piAUC and peak) with increased secre-
tion after CDCA compared with placebo, whereas UDCA
did not stimulate PYY secretion (Table 2, Fig. 1C). Intake
of CDCA resulted in a prolonged PYY secretion, i.e. con-
centrations did not return to basal level within 180 minutes
after intake (P = 0.02). Secretion of neurotensin also dif-
fered between study days (ANOVA: P < 0.01 for both
piAUC and peak) with clearly enhanced secretion after
CDCA in contrast with no stimulation during UDCA com-
pared with placebo (Table 2, Fig. 1E). GIP was not affected
by any of the two BAs (Table 2, Fig. 1H). Peak of CCK
concentrations (ANOVA: P = 0.05) tended to increase
after CDCA (P = 0.06) but not after UDCA (P = 0.49)
compared with placebo, while piAUC was unaffected by
both BAs (ANOVA: P = 0.57; Table 2, Fig. 1G).
Plasma TBA and FGF19
Both plasma TBA and FGF19 differed between study days
(ANOVA: P < 0.01 for both piAUC and peak). CDCA
increased plasma TBA significantly, while only a slight
numerical increase in piAUC (P = 0.07) and no change
in peak concentrations (P = 0.41) were observed follow-
ing UDCA (Table 3, Fig. 2A) compared with placebo.
FGF19 concentrations increased after CDCA compared
with placebo (P ≤ 0.01 for both piAUC and peak) and
were unchanged following UDCA (P = 0.91 for piAUC,
P = 0.16 for peak; Table 3, Fig. 2B).
VAS ratings, blood pressure, and heart rate
Oral intake of BAs neither changed VAS ratings for appe-
tite perception (hunger or satiety), nausea, or stomach
pain nor affected blood pressure or heart rate (data not
shown). However, one patient did report increased VAS
(64 mm from baseline) in stomach pain 30 min after
intake of CDCA. This was followed by a single defecation
after which VAS returned to baseline.
Discussion
We investigated the effects of oral administration of two
different bile acids (BAs), ursodeoxycholic acid (UDCA)
and chenodeoxycholic acid (CDCA) in RYGB-operated
participants.
We found that administration of the primary BA,
CDCA, stimulated secretion of GLP-1, PYY, neurotensin,
C-peptide and glucagon, whereas plasma glucose, CCK
and GIP concentrations were unaffected. In contrast,
ingestion of the secondary BA, UDCA, did not affect any
hormone concentrations significantly. Interestingly,
CDCA induced peak GLP-1 concentrations of 29 pmol/L
and notably, this was obtained without concomitant
intake of nutrients or calories. A GLP-1 response of this
size corresponds to the normal GLP-1 secretion during a
liquid mixed-meal in non-operated obese subjects (Jør-
gensen et al. 2012) and is much higher than previously
reported after upper intestinal infusions of BAs (1250 mg
CDCA (Hansen et al. 2016), 2100 mg CDCA (Meyer-Ger-
spach et al. 2013), or 2000 mg taurocholic acid (TCA)
(Wu et al. 2013b)), where maximal mean peak GLP-1
concentrations reached 17 pmol/L (Hansen et al. 2016).
Studies with rectal administrations of BAs (TCA) have
shown a more pronounced GLP-1 secretory response with
peak concentrations up to ~35 pmol/L (Adrian et al.
2012; Wu et al. 2013a). After RYGB, passage of orally
ingested substances is accelerated through the gastric
pouch that drains directly into the lower part of the jeju-
num (Dirksen et al. 2013a); accordingly, oral intake of
BAs corresponds to administration directly into distal
parts of the small intestine. Thus, our findings add to the
existing literature and support that GLP-1 secretion after
BA administration depends on the site of delivery. This
may be particularly relevant for unconjugated BAs, which
normally will be passively absorbed in the upper intestine
before reaching the distal small intestine after oral
administration in non-RYGB individuals (Ma and Patti
2014).
In RYGB-operated patients, however, GLP-1 secretion
may reach peak concentrations up to ~150 pmol/L after a
liquid mixed meal (Jørgensen et al. 2012), hence CDCA
does not seem to activate the secretory machinery of the
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Figure 1. GLP-1 (A), glucose (B), PYY (C), C-peptide (D), neurotensin (E), glucagon (F), CCK (G), and GIP (H) concentrations in response to oral
intake of placebo (solid line, black circles), ursodeoxycholic acid (UDCA; solid line, white squares) and chenodeoxycholic acid (CDCA; dotted
line, white triangles) in RYGB-operated participants. Data are presented as mean + SEM.
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L-cell to its full capacity—at least not when BAs are
ingested alone without nutrients. Nevertheless, the GLP-1
secretion after CDCA was associated with a small increase
in C-peptide concentrations even without co-ingestion of
nutrients and without changes in glucose. Whether this
insulin secretion was actually mediated by GLP-1 cannot
be determined from this study, but if so, we would not
expect a major response given that the insulinotropic
effect of GLP-1 is glucose-dependent (Hvidberg et al.
1994).
Administration of BAs has been demonstrated to stim-
ulate PYY in vitro via activation of TGR5 (Bala et al.
2014). Stimulation also appears to occur in vivo (Adrian
et al. 1993, 2012; Meyer-Gerspach et al. 2013; Wu et al.
2013a), as demonstrated after intraduodenal (Meyer-Ger-
spach et al. 2013), intracolonic (Adrian et al. 1993), and
rectal (Adrian et al. 2012) infusions of BAs (CDCA,
deoxycholate (DCA) and TCA, respectively), and further
supported by our findings of an increase in PYY concen-
trations after oral intake of CDCA. Notably, markedly
higher peak concentrations of PYY have been reported
after ingestion of mixed meals in both non-operated sub-
jects and RYGB-operated patients (Jacobsen et al. 2012)
as well as after rectal administration of BAs (Adrian et al.
2012; Wu et al. 2013a). Neurotensin appears to be a
co-player with GLP-1 and PYY in regulating metabolic
Table 3. Total bile acid (TBA) and fibroblast growth factor 19 (FGF19) concentrations in response to bile acid administration.
Placebo
n = 10
CDCA
n = 8
UDCA
n = 11 ANOVA
Placebo
vs. CDCA
Placebo
vs. UDCA
Basal TBA
(lmol/L)
5.8  1.8 2.8  0.6 2.6  0.8 P = 0.08
Peak TBA
(lmol/L)
7.1  1.8 54.0  12.5 13.9  2.6 P < 0.01 P < 0.01 P = 0.41
piAUC TBA
(lmol/L 9 min)
32.1  14.8 2844  567 767  139 P < 0.01 P < 0.01 P = 0.07
Basal FGF19
(pg/mL)
270  93.9 244  91.3 149  22.1 P = 0.26
Peak FGF19
(pg/mL)
304  90.2 776  153 177  31.8 P < 0.01 P = 0.01 P = 0.16
piAUC FGF19
(pg/mL 9 min)
2104  910 37174  9049 1477  926 P < 0.01 P < 0.01 P = 0.91
CDCA, chenodeoxycholic acid; UDCA, ursodeoxycholic acid. Data are presented as mean  SEM.
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Figure 2. Total bile acids (TBA) (A) and fibroblast growth factor 19 (FGF19) (B) concentrations in response to oral intake of placebo (solid line,
black circles), ursodeoxycholic acid (UDCA; solid line, white squares) and chenodeoxycholic acid (CDCA; dotted line, white triangles) in RYGB-
operated participants. Data are presented as mean + SEM.
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functions, including appetite, and glucose homeostasis
regulation (Svendsen et al. 2015; Grunddal et al. 2016)
and as for GLP-1 and PYY, RYGB is associated with
greatly exaggerated postprandial secretion of this peptide
(Dirksen et al. 2013b). We found that administration of
CDCA stimulated secretion of neurotensin and the secre-
tory profile was rather similar to that of GLP-1. Intere-
stingly, the secretory profiles of GLP-1 and neurotensin
appeared to differ from the profile of PYY on the CDCA
day, with GLP-1 and neurotensin returning to baseline
level after 120–150 min, whereas PYY levels remained
high throughout the 180 min follow-up. The present
observation is in contrast to the parallel dynamic changes
of the hormones often observed during a mixed meal test
(Jacobsen et al. 2012). A similar prolonged secretion of
PYY has not been reported previously and caused us to
speculate that CDCA may, in succession, first stimulate
the L-cells in the proximal ileum followed by stimulation
of the L-cells in the distal part of the intestine including
the colon. Indeed, there is data to suggest that the L-cells
in the distal part of the gut primarily secrete PYY, as
demonstrated in several animal models (Svendsen et al.
2015; Grunddal et al. 2016; Wewer Albrechtsen et al.
2016). Our results suggest that CDCA is able to simulta-
neously enhance the secretion of several enteroendocrine
cell products (GLP-1, neurotensin, PYY), which could
have synergistic beneficial actions with respect to appetite
inhibition (Schmidt et al. 2016).
We observed increased concentrations of glucagon
only after CDCA intake, which is in line with previous
observations (Meyer-Gerspach et al. 2013; Hansen et al.
2016). It is well established that RYGB-operated patients
have increased postprandial glucagon concentrations
concomitantly with high glucose, GLP-1 and insulin
concentrations (Jacobsen et al. 2012; Jørgensen et al.
2013; Svane et al. 2016). The cause of this paradoxical
hyperglucagonemia is still unknown, but extrapancreatic
secretion may occur, as observed after pancreatectomy
using Whipple procedure (Holst et al. 1983; Lund et al.
2016), which implies similar gastrointestinal reconstruc-
tions as after RYGB. Another explanation of our fin-
dings could be a direct stimulatory effect of CDCA on
the alpha-cells in pancreas. However, in contrast with
the case for CDCA-stimulated GLP-1 secretion (Brighton
et al. 2015), activation of TGR5 is unlikely be involved
as the receptor has been found not to be expressed in
primary murine alpha-cells (Kuhre et al. 2016). BA
administration did not change GIP or CCK concentra-
tions in our study, although there was a tendency for
slightly increased peak concentrations of CCK after
CDCA. In line with these results, other studies have
demonstrated increased CCK after intraduodenal
(Meyer-Gerspach et al. 2013) and intragastric (Hansen
et al. 2016) CDCA infusions and no effect on GIP con-
centrations (Hansen et al. 2016).
In this study, we found a marked difference in gut
hormone responses between administration of CDCA
(1250 mg) and UDCA (750 mg). As this study was an
exploratory study of CDCA and UDCA in RYGB-ope-
rated participants, we chose to use the highest recom-
mended daily dose for each bile acid according to the
label, which was 1250 mg for CDCA and 750 mg for
UDCA. The study was therefore not designed to com-
pare the relative effects of CDCA and UDCA on gut
hormone secretion, but rather to investigate whether
these BAs stimulated gut hormone secretions at all.
Dose-response studies of different BAs with respect to
GLP-1 secretion have not been performed in humans,
but an in vitro study has demonstrated that CDCA acti-
vates TGR5 while UDCA was without effect (at equal
concentrations) (Kawamata et al. 2003). Differences in
the absorption of the two BAs could also be of impor-
tance for the ability to stimulate release of gut hor-
mones. In a recent study, BAs activated basolateral but
not apically located TGR5 receptors, indicating that BAs
must be absorbed from the intestinal lumen before they
can stimulate GLP-1 secretion (Brighton et al. 2015). In
addition to the acute TGR5 mediated effects, BAs may
have additional and potentially longer lasting effects via
activation of the nuclear receptor FXR (Ma and Patti
2014). Activation of FXR regulates insulin secretion
(Renga et al. 2010) and induces expression and secretion
of FGF19, which stimulates glycogen synthesis and
reduce hepatic gluconeogenesis (Ma and Patti 2014).
Knockout of FXR in mice eliminated the beneficial
effects of sleeve gastrectomy on glucose metabolism
(Ryan et al. 2014). Activation of FXR does not seem to
have stimulatory effects on GLP-1 secretion (Brighton
et al. 2015) and may even decrease secretion (Trabelsi
et al. 2015). CDCA is the most potent ligand for stimu-
lating and activating FXR, while UDCA has negligible
FXR-activities (Ma and Patti 2014). Whether a single
administration of BAs can activate the FXR-pathway is
unknown, but in this study we demonstrated that CDCA
increased FGF19 secretion after 90 min, although we do
not know whether this was indeed a result of FXR path-
way activation.
After RYGB, plasma BA concentrations increase both
in the fasting state and postprandially (Pournaras et al.
2012; Kohli et al. 2013a; Steinert et al. 2013; Werling
et al. 2013; Jørgensen et al. 2015). Endogenously secreted
BAs in humans consist mostly of the primary BAs, cholic
acid (CA) and CDCA and the secondary BA, DCA; most
BAs are conjugated with glycine and the remaining with
taurine (Werling et al. 2013; Ma and Patti 2014; Jørgen-
sen et al. 2015). Studies in rodent models strongly
2017 | Vol. 5 | Iss. 3 | e13140
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support BAs as key mediators of the improvements in
glucose metabolism after RYGB and sleeve gastrectomy
(Pournaras et al. 2012; Kohli and Seeley 2013; Kohli et al.
2013b; Ryan et al. 2014; Baud et al. 2016), but inconsis-
tencies with respect to timing of the postoperative
changes in BAs and the effects of RYGB on GLP-1 secre-
tion and glucose metabolism are observed in human stud-
ies (Ahmad et al. 2013; Steinert et al. 2013; Dutia et al.
2015; Jørgensen et al. 2015). Notably, administration of
exogenous BAs causes much higher plasma TBA concen-
trations (obviously depending of the BA dosage) than
seen in RYGB-operated patients. In our study, CDCA
administration increased TBA concentrations up to 5–fold
with peak concentrations of 55 lmol/L. In comparison,
postprandial TBA concentrations after RYGB reach peak
concentrations of only 8–9 lmol/L 12–15 months postop-
eratively (Werling et al. 2013; Jørgensen et al. 2015).
Thus, despite our findings of increased GLP-1 secretion
in RYGB-operated participants in response to pharmaco-
logical doses of CDCA, we cannot make any conclusions
regarding the possible physiological effects of endogenous
BAs for improved glucose metabolism after RYGB, which
obviously is of great interest. The use of only one dose of
each BA, and two different doses of BAs, further limit the
conclusions with respect to relative effects of CDCA ver-
sus UDCA on gut hormone secretion. Another interesting
research question is whether exogenous administered BAs
can be used to enhance endogenous gut hormone secre-
tion in combination with meal intake in obese and
RYGB-operated patients. If so, BA administration could
be a potential treatment for patients with obesity in gen-
eral, and in particular RYGB-operated patients with inad-
equate glycemic control or poor weight loss responses
after surgery.
In conclusion, oral administration of the bile acid,
chenodeoxycholic acid, to RYGB-operated participants
stimulated GLP-1, PYY, neurotensin, C-peptide, and glu-
cagon secretion in the absence of nutrients and without
changed glucose concentration. No effect was seen follow-
ing ursodeoxycholic acid. Chenodeoxycholic acid may
therefore be viewed as a molecular enhancer of several
gut hormones of potential importance for the future
treatment of diabetes and obesity.
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